Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary – ...

Akeso announces China NMPA accepts sNDA for ivonescimab in combo with chemotherapy to treat advanced squamous NSCLC: Honk Kong Tuesday, July 29, 2025, 16:00 Hrs [IST] Akeso, Inc., ...

Months have passed since Mary Barnes had a double mastectomy to treat an “aggressive” form of breast cancer. Now her ...

Atezolizumab enhances long-term outcomes in triple-negative breast cancer, revealing promising insights on ctDNA as a prognostic biomarker.

Merck's Q2 2025 earnings call reveals revenue of $15.8B, strategic growth plans with a $3B reinvestment initiative, and confidence in driving ...

Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection ...

Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends | DelveInsight The adrenocortical carcinoma market in the 7MM is anticipated to boost during the ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary - The average age of cancer patients is getting younger, ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

Despite being significantly lower than the 200% rate threatened by Trump, the deal is set to ramp up drug costs by billions.